MaxCyte acquires SeQure Dx to bolster gene therapy services
LONDON: MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering company, announced the acquisition of SeQure Dx, a market leader in editing assessment services for cell and gene therapies. The acquisition aims to enhance MaxCyte’s offerings in both ex vivo…